1. A single cysteine residue in vimentin regulates long non-coding RNA XIST to suppress epithelial-mesenchymal transition and stemness in breast cancer

    This article has 6 authors:
    1. Saima Usman
    2. W Andrew Yeudall
    3. Muy-Teck Teh
    4. Fatemah Ghloum
    5. Hemanth Tummala
    6. Ahmad Waseem
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This study presents a valuable finding that C238 in vimentin regulates long non-coding RNA XIST to suppress EMT and thereby Xist may be a therapeutic target in breast cancer. The evidence supporting the claims of the authors is solid, although the improvement of data visibility and presentation would have strengthened the study. The work will be of interest to scientists working in the field of BCs.

    Reviewed by eLife

    This article has 3 evaluationsAppears in 1 listLatest version Latest activity
  2. Intrinsic bioenergetic adaptations compensate for reduced mitochondrial content in HER2-driven mammary tumors

    This article has 10 authors:
    1. Sara M Frangos
    2. Henver S Brunetta
    3. Dongdong Wang
    4. Maria Joy Therese Jabile
    5. David WL Ma
    6. William J Muller
    7. Cezar M Khursigara
    8. Kelsey H Fisher-Wellman
    9. Gregory R Steinberg
    10. Graham P Holloway
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This useful study uses the MMTV-Neu-YD5 mouse model for HER2-dependent breast cancer to generate transcriptomic and proteomic datasets from extracted primary tumour samples. The data sets generated appear to be solid and will be of interest to the community. However, mechanistic studies to support the conclusion that mitochondrial function is increased in the tumours remain incomplete and would benefit from experiments that would directly interrogate aspects such as cellular heterogeneity, and signalling.

    Reviewed by eLife

    This article has 3 evaluationsAppears in 1 listLatest version Latest activity
  3. Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer

    This article has 14 authors:
    1. Yijia Hua
    2. Ningjun Duan
    3. Chunxiao Sun
    4. Fan Yang
    5. Min Tian
    6. Yanting Sun
    7. Shuhan Zhao
    8. Jue Gong
    9. Qian Liu
    10. Xiang Huang
    11. Yan Liang
    12. Ziyi Fu
    13. Wei Li
    14. Yongmei Yin
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the authors may want to validate their results in additional cell lines to strengthen their conclusions. Moreover, the authors should clarify the source of patient samples and why the manuscript focused on epigenetic regulations instead of major transcription factors. The work will be of interest to scientists working in the field of breast cancer.

    Reviewed by eLife

    This article has 4 evaluationsAppears in 1 listLatest version Latest activity
  4. NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in Solitary Fibrous Tumors

    This article has 7 authors:
    1. Connor M Hill
    2. Alexandra Indeglia
    3. Francis Picone
    4. Maureen E Murphy
    5. Cara Cipriano
    6. Robert G Maki
    7. Alessandro Gardini
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This study provides compelling data regarding the molecular characterization of a rare tumor type with few treatment options. This fundamental work significantly advances our mechanistic understanding of solitary fibrous tumours, a critical first step towards targeted precision medicine approaches. The results of this study will be of broad interest to cancer biologists and experimental oncologists.

    Reviewed by eLife

    This article has 5 evaluationsAppears in 1 listLatest version Latest activity
  5. Deuterium metabolic imaging phenotypes mouse glioblastoma heterogeneity through glucose turnover kinetics

    This article has 9 authors:
    1. Rui Vasco Simoes
    2. Rafael Neto Henriques
    3. Jonas L Olesen
    4. Beatriz M Cardoso
    5. Francisca F Fernandes
    6. Mariana AV Monteiro
    7. Sune N Jespersen
    8. Tânia Carvalho
    9. Noam Shemesh
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This study provides a valuable approach to image and analyze in vivo metabolic flux through glucose turnover kinetics in glioblastoma tumor microenvironments. The evidence for the method's validity is convincing, which establishes the dynamic Deuterium Metabolic Imaging technique as an effective tool enabling non-invasive exploration of various tumors.

    Reviewed by eLife

    This article has 8 evaluationsAppears in 1 listLatest version Latest activity
  6. Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer

    This article has 10 authors:
    1. Tackhoon Kim
    2. Byung-Sun Park
    3. Soobeen Heo
    4. Heeju Jeon
    5. Jaeyeal Kim
    6. Donghwa Kim
    7. Sang Kook Lee
    8. So-Youn Jung
    9. Sun-Young Kong
    10. Timothy K Lu
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This study presents a valuable finding that synthetically lethal kinase genes FYN and KDM4 may play a role in drug resistance to kinase inhibitors in TNBC. The evidence supporting the claims of the authors is solid, although the exploration of the upstream mechanisms regulating KDM4A or the downstream pathways through which FYN upregulation confers drug resistance would have strengthened the study. The work will be of interest to medical biologists working in the field of breast cancer.

    Reviewed by eLife

    This article has 6 evaluationsAppears in 1 listLatest version Latest activity
  7. Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs and CD8+ T cells

    This article has 24 authors:
    1. Fangyuan Dong
    2. Shan Zhang
    3. Kaiyuan Song
    4. Luju Jiang
    5. Li-Peng Hu
    6. Qing Li
    7. Xue-Li Zhang
    8. Jun Li
    9. Mingxuan Feng
    10. Zhi-Wei Cai
    11. Hong-Fei Yao
    12. Rong-Kun Li
    13. Hui Li
    14. Jie Chen
    15. Xiaona Hu
    16. Jiaofeng Wang
    17. Chongyi Jiang
    18. Helen He Zhu
    19. Cun Wang
    20. Lin-Tai Da
    21. Zhi-Gang Zhang
    22. Zhijun Bao
    23. Xu Wang
    24. Shu-Heng Jiang
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous report on directly targeting tumor cells via glucose transporter 1 (GLUT1), they tried to uncover additional working mechanisms of citalopram in HCC treatment in the current study. The data here suggested that citalopram may regulate the phagocytotic function of TAM via C5aR1 or CD8+T cell function to suppress HCC growth in vivo.

    Reviewed by eLife

    This article has 4 evaluationsAppears in 1 listLatest version Latest activity
  8. Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis

    This article has 31 authors:
    1. Zuzana Outla
    2. Gizem Oyman-Eyrilmez
    3. Katerina Korelova
    4. Magdalena Prechova
    5. Lukas Frick
    6. Lenka Sarnova
    7. Piyush Bisht
    8. Petra Novotna
    9. Jan Kosla
    10. Patricia Bortel
    11. Yasmin Borutzki
    12. Andrea Bileck
    13. Christopher Gerner
    14. Mohammad Rahbari
    15. Nuh Rahbari
    16. Emrullah Birgin
    17. Bibiana Kvasnicova
    18. Andrea Galisova
    19. Katerina Sulkova
    20. Andreas Bauer
    21. Njainday Jobe
    22. Ondrej Tolde
    23. Eva Sticova
    24. Daniel Rösel
    25. Tracy O'Connor
    26. Martin Otahal
    27. Daniel Jirak
    28. Mathias Heikenwälder
    29. Gerhard Wiche
    30. Samuel M Meier-Menches
    31. Martin Gregor
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This valuable study investigated the role of PLECTIN, a cytoskeletal crosslinker protein, in hepatocellular carcinoma development and progression. Using a liver-specific Plectin knockout mouse model, the authors showed solid evidence that PLECTIN is critical for hepatocarcinogenesis, since inhibition of PLECTIN suppressed tumor formation in multiple models. They also show that PLECTIN is key for HCC invasion and metastasis. They show a correlation between PLECTIN inhibition and attenuated FAK, MAPK/ERK, and PI3K/AKT signaling.

    Reviewed by eLife

    This article has 9 evaluationsAppears in 1 listLatest version Latest activity
  9. Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

    This article has 6 authors:
    1. Jessica Armand
    2. Sungsoo Kim
    3. Kibum Kim
    4. Eugene Son
    5. Minah Kim
    6. Hee Won Yang
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in combination with CDK2 inhibitors, significantly suppresses the growth of drug-resistant cancer cells. The findings are supported by compelling evidence from both in vitro cell line experiments and in vivo mouse models, highlighting the therapeutic potential of maintaining CDK4/6 inhibitors beyond disease progression. Additionally, the identification of cyclin E overexpression as a key driver of resistance offers a target that will be of value for future therapeutic strategies, potentially improving outcomes for patients with advanced breast cancer.

    Reviewed by eLife

    This article has 5 evaluationsAppears in 1 listLatest version Latest activity
  10. Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning

    This article has 12 authors:
    1. Gabriella O Estevam
    2. Edmond Linossi
    3. Jingyou Rao
    4. Christian B Macdonald
    5. Ashraya Ravikumar
    6. Karson M Chrispens
    7. John A Capra
    8. Willow Coyote-Maestas
    9. Harold Pimentel
    10. Eric A Collisson
    11. Natalia Jura
    12. James S Fraser
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      This manuscript provides an important overview of potential resistance mutations within MET Receptor Tyrosine Kinase. The evidence supporting the findings is convincing - it should be pointed out that the approach is comparatively new for the application of protein kinases and the results are therefore of potentially great value. The results will be of value for clinicians facing drug resistance mutations, computational biologists who are training models of drug resistance mechanisms and biologists with an interest in cell signaling.

    Reviewed by eLife

    This article has 8 evaluationsAppears in 1 listLatest version Latest activity
Previous Page 3 of 38 Next